Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$57 Mln
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
--
Debt to Equity
0.01
ROE
-0.29 %
ROCE
-28.21 %
Div. Yield
0 %
Book Value
3.39
EPS
-1.13
CFO
$-235.97 Mln
EBITDA
$-293.01 Mln
Net Profit
$-277.45 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pmv Pharmaceuticals Inc (PMVP)
| -28.48 | -14.96 | -18.18 | -37.57 | -59.28 | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Pmv Pharmaceuticals Inc (PMVP)
| -51.00 | -64.37 | -62.34 | -62.45 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.79 | 9,808.03 | 20.22 | 23.13 | |
| 289.41 | 8,956.09 | 22.08 | 58.42 | |
| 26.79 | 9,559.25 | -- | -28.77 | |
| 103.51 | 10,030.35 | 30.81 | 14.16 |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small... molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. Address: 400 Alexander Park Drive, Princeton, NJ, United States, 08540 Read more
Co-Founder, CEO, President & Director
Dr. David H. Mack Ph.D.
Co-Founder, CEO, President & Director
Dr. David H. Mack Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pmv Pharmaceuticals Inc (PMVP) stood at $ 191 Mln as on 31-Dec-24
The share price of Pmv Pharmaceuticals Inc (PMVP) is $1.08 (NASDAQ) as of 23-Apr-2025 13:41 EDT. Pmv Pharmaceuticals Inc (PMVP) has given a return of -59.28% in the last 3 years.
Pmv Pharmaceuticals Inc (PMVP) has a market capitalisation of $ 57 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Pmv Pharmaceuticals Inc (PMVP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pmv Pharmaceuticals Inc (PMVP) and enter the required number of quantities and click on buy to purchase the shares of Pmv Pharmaceuticals Inc (PMVP).
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. Address: 400 Alexander Park Drive, Princeton, NJ, United States, 08540
The CEO & director of Dr. David H. Mack Ph.D.. is Pmv Pharmaceuticals Inc (PMVP), and CFO & Sr. VP is Dr. David H. Mack Ph.D..
There is no promoter pledging in Pmv Pharmaceuticals Inc (PMVP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Pmv Pharmaceuticals Inc (PMVP) | Ratios |
|---|---|
|
Return on equity(%)
|
-29.23
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pmv Pharmaceuticals Inc (PMVP) was $0 Mln.
